NCT05380492View on ClinicalTrials.gov

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Age-related Macular DegenerationGeographic Atrophy
Interventions
BIOLOGICAL

VOY-101

Intravitreal injection of VOY-101

Trial Locations (3)

77401

Retina Consultants of Texas, Bellaire

84112

University of Utah, Salt Lake City

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Perceive Biotherapeutics, Inc.

INDUSTRY

NCT05380492 - Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter